InnovAge Holding Corp.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $INNV in the last 30 days.
See all $INNV insider activity →InnovAge Holding (INNV) reported a Q4 profit of $8.29M, up from a loss, with revenue rising to $261.95M. Management provided 2027 revenue guidance. Shares surged 107% YTD. Analysts see fair value at $10, suggesting a 7.5% overvaluation, while a DCF model values it at $29.55. The company faces cost pressures and competition.
InnovAge Holding Corp. (INNV) reported Q4 2026 revenue of $261.95M, beating estimates, but EPS of $0.06 missed expectations. Full-year revenue rose 15.9% to $989.71M, while net loss narrowed to $0.68M. Shares rose 9.03% after-hours. FY2027 guidance projects revenue of $1.05B-$1.085B and Adjusted EBITDA of $105M-$115M.
InnovAge (INNV) reported fiscal 2026 revenue of $989.7M, up 15.9%, with adjusted EBITDA of $94.6M. Adjusted EBITDA margin rose to 9.6% from 4.0%. GAAP net loss narrowed to $0.7M. Fiscal 2027 guidance projects revenue of $1.05B-$1.085B and adjusted EBITDA of $105M-$115M. The company did not forecast GAAP net income due to estimation challenges.
Over the past 7 days, AlphAI's AI scored 11 news stories mentioning INNV (InnovAge Holding Corp.). Coverage has skewed bullish: 8 bullish, 3 neutral, and 0 bearish.
Recent INNV coverage spans earnings and financial news.
The article frames a profitability inflection plus 2027 revenue guidance as the core driver of the stock’s strong momentum, while also flagging cost and new-center losses as key downside risks.
Positive revenue beat and raised guidance suggest upside potential, while EPS miss may temper enthusiasm.
Strong earnings beat and upbeat guidance may lift the stock, but higher litigation cost adjustments add risk.
Guidance raises revenue expectations while assuming modest rate growth, suggesting modest upside for the stock.
Guidance above expectations and a strong share price reaction suggest upside potential if the company meets its revenue target.
AlphAI scores every news story that mentions INNV with an AI model for sentiment and relevance, and aggregates insider trades from InnovAge Holding Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
InnovAge Holding (INNV) reported a Q4 profit of $8.29M, up from a loss, with revenue rising to $261.95M. Management provided 2027 revenue guidance. Shares surged 107% YTD. Analysts see fair value at $10, suggesting a 7.5% overvaluation, while a DCF model values it at $29.55. The company faces cost pressures and competition.
7 min readInnovAge Holding Corp. (INNV) reported Q4 2026 revenue of $261.95M, beating estimates, but EPS of $0.06 missed expectations. Full-year revenue rose 15.9% to $989.71M, while net loss narrowed to $0.68M. Shares rose 9.03% after-hours. FY2027 guidance projects revenue of $1.05B-$1.085B and Adjusted EBITDA of $105M-$115M.
2 min readInnovAge (INNV) reported fiscal 2026 revenue of $989.7M, up 15.9%, with adjusted EBITDA of $94.6M. Adjusted EBITDA margin rose to 9.6% from 4.0%. GAAP net loss narrowed to $0.7M. Fiscal 2027 guidance projects revenue of $1.05B-$1.085B and adjusted EBITDA of $105M-$115M. The company did not forecast GAAP net income due to estimation challenges.
2 min readInnovAge Holding Corp. completed 'InnovAge 2.0' in 2026, focusing on operational improvements. 'InnovAge 3.0' will prioritize scaling and expansion. For 2027, the company projects 1.5% to 2.0% net Medicare rate increases and revenue of $1.05B to $1.085B, with growth driven by enrollment and utilization management. Management prefers M&A over de novo centers for capital allocation.
3 min readInnovAge Holding Corp (INNV) reported fiscal 2026 results and fiscal 2027 guidance of $1.05bn to $1.085bn in revenue. Shares rose 13.12% to $11.90. Management reported a 175% increase in adjusted EBITDA, though GAAP net income showed volatility. The company plans to scale operations and expand value-based care. Three private-equity sponsors filed SEC forms around the earnings release.
2 min readAnalysts updated price targets for several companies. Rosenblatt raised IMAX's target to $65, BTIG cut CAN's to $2, Piper Sandler adjusted TTAN and BRZE targets, Needham boosted VRNS, BTIG reduced BSX, Wedbush increased PHVS, Canaccord raised CHYM, Freedom Capital upped ABM, and Keybanc lifted INNV. All analysts maintained their respective ratings.
2 min readInnovAge (INNV) stock rose 14.6% in pre-market trading after reporting fiscal Q4 and full-year 2026 results. Adjusted EBITDA increased 175% to $94.6M, revenue grew 15.9% to $989.7M, and net loss narrowed to $0.7M. The company issued fiscal 2027 guidance targeting revenue of $1.05B-$1.085B and adjusted EBITDA of $105M-$115M. CEO Patrick Blair highlighted a strategic focus on scaling through technology, AI, and potential acquisitions.
2 min readModular Medical (MODD) rose 13.48% in overnight trading after a 23.37% drop earlier, planning a 2026 launch for its Pivot tubeless patch pump. Jin Medical (ZJYL) gained 20.79% with no specific news. InnovAge (INNV) increased 9.51% after reporting a 15.9% revenue rise. Pyxis Oncology (PYXS) climbed 5% ahead of a key clinical update. Pulse Biosciences (PLSE) fell 2.48% despite clinical trial progress. Dermata (DRMA) rose 7.20% after launching its Tome skincare brand. Dogwood Therapeutics (DWTX) ga
3 min readInnovAge reported Q4 cost of care rose 16.1% to $312.1M. It held $97.9M in cash, $43.4M in short-term investments, and $63.3M in debt. The company projected fiscal 2027 revenue of $1.05B-$1.085B, adjusted EBITDA of $105M-$115M, and 5%-7.5% growth. It outlined 'InnovAge 3.0' strategy, focusing on scaling and acquisitions.
2 min readInnovAge Holding Corp. (INNV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 INNOVAGE ANNOUNCES FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR ENDED JUNE 30, 2026 DENVER, CO., September 8, 2026 - InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to
2 min read
